Modality
Radioligand
MOA
FcRni
Target
KRASG12D
Pathway
RAS/MAPK
PVPancreatic Ca
Development Pipeline
Preclinical
~Sep 2019
→ ~Dec 2020
Phase 1
Mar 2021
→ Sep 2026
Phase 1Current
NCT06982748
1,949 pts·PV
2021-03→2026-09·Recruiting
NCT06232922
2,135 pts·Pancreatic Ca
2022-12→TBD·Completed
4,084 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-062mo awayOrphan Drug· PV
2026-09-065mo awayPh2 Data· PV
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1/2
Recruit…
P1/2
Complet…
Catalysts
Orphan Drug
2026-06-06 · 2mo away
PV
Ph2 Data
2026-09-06 · 5mo away
PV
RecruitingCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06982748 | Phase 1/2 | PV | Recruiting | 1949 | DAS28 |
| NCT06232922 | Phase 1/2 | Pancreatic Ca | Completed | 2135 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | CD38 |